Drug maker Lupin Tuesday said it has appointed Alok Sonig as CEO US Generics and Global Head Generics R&D & Biosimilars.
Sonig will lead and have overall responsibility for the US Generics business, including R&D activities in India and the US, and the commercial side of the American business.
He will also be responsible for Lupin's global biosimilars business.
Most recently, Sonig was CEO of Developed Markets (US, Canada, Europe and Japan) at Dr Reddy's Laboratories. Prior to that Sonig spent nearly 15 years at Bristol-Myers Squibb, where he held several senior positions.
"His global experience, strategic perspective, and operational focus will help accelerate our team's efforts to strengthen and evolve our US generics business as we execute on near-term growth opportunities and navigate new platforms in complex generics and biosimilars," Lupin CEO Vinita Gupta said in a statement.
Sonig will be based out of Somerset, New Jersey and will report to Vinita Gupta and Nilesh Gupta Managing Director, Lupin.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app